Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing changes in share interests for Sir Andrew Witty, a Director of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of director share transactions rather than a financial performance report.
Material Changes and Transactions
The following transactions involving Sir Andrew Witty were reported for May 1, 2014:
- Gift Transfer: Transfer of 500 Ordinary Shares to each of his two children.
- Share Sales and Repurchases: Sale of 731 Ordinary Shares and repurchase of 724 Ordinary Shares transferred into an ISA. The prices were 1629.0550p and 1629.4650p per share, respectively.
- Option Exercise and Sale: Exercise of options over 100,000 Ordinary Shares granted on December 2, 2004, at an exercise price of £11.23 per share. Immediately following the exercise, 100,000 Ordinary Shares were sold at £16.385 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of specific director share transactions in accordance with the Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held by Sir Andrew Witty post-transaction to assess ongoing alignment with company interests.
- Confirm the timing of the option exercise relative to any non-public information that may have been available on May 1, 2014.
- Review the company's broader insider trading policies to ensure these transactions were pre-cleared and compliant.